Dr. Reichert, Executive Director of The Antibody Society, is an internationally-recognized expert in the development of antibody and peptide therapeutics. She is Founder and Managing Director of Reichert Biotechnology Consulting LLC, a biopharmaceutical business intelligence research firm, and Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development. Dr. Reichert has published extensively on development trends for antibody therapeutics, and she has presented her research results as an invited speaker at conferences held worldwide. She is co-editor of the Handbook of Therapeutic Antibodies, and serves on the editorial boards of several biomedical journals.
Dr. Reichert received her PhD in Chemistry from the University of Pennsylvania and did her post-doctoral training at Harvard Medical School.
Dr. Alicia Chenoweth is a postdoctoral research associate in the Cancer Antibody Discovery and Immunotherapy group led by Prof. Sophia Karagiannis at King’s College London. Her work is focused on Fc engineering of antibodies for breast cancer therapy to better engage and influence the immune microenvironment. She received her PhD in Melbourne, Australia, under the supervision of Prof. Mark Hogarth, focusing on the interactions of human and non-human primate IgG antibodies with Fc receptors, and the impact of IgG Fc modification on immune cell function. Dr. Chenoweth is currently the co-chair of the Gordon Research Seminar for Antibody Biology and Engineering, to be held in 2022.
Dr. Silvia Crescioli is a senior post doc at King’s College London in Prof. Sophia Karagiannis’ Cancer Antibody Discovery & Immunotherapy Group, where she leads and supervises several projects focused on different areas of cancer immunology and immunotherapy, such as the study of B cells in cancer, antigen/antibody discovery, ADC development, and antibody production, engineering and glycoengineering. Dr. Crescioli received her PhD in Biomedical Sciences, Experimental Oncology, from the University of Florence.
